title: The effects of rituximab treatment during pregnancy on a neonate.
abstract: A 35-year old woman developed Burkitt's lymphoma and was treated with rituximab and CHOP therapy early during pregnancy. Monitoring of rituximab concentrations and B-cell counts in the child revealed a transient complete B-cell depletion associated with high rituximab cord blood concentrations. B-cell recovery was fast, showing a regular immunophenotype without loss of CD20 antigen, no functional deficits and adequate vaccination IgG titers.
authors.forename: Birte
authors.initials: B
authors.lastname: Friedrichs
authors.forename: Markus
authors.initials: M
authors.lastname: Tiemann
authors.forename: Hans
authors.initials: H
authors.lastname: Salwender
authors.forename: Karl
authors.initials: K
authors.lastname: Verpoort
authors.forename: Michael K
authors.initials: MK
authors.lastname: Wenger
authors.forename: Norbert
authors.initials: N
authors.lastname: Schmitz
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000097:blood; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002051:Burkitt Lymphoma / Q000097:blood / Q000188:drug therapy; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005312:Fetal Blood / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn / Q000097:blood*; D011241:Prednisone / Q000008:administration & dosage; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000097:blood*; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone